Key points
- Myo-inositol and D-chiro-inositol are different stereoisomers associated with insulin and gonadotropin signaling pathways.
- In PCOS, inositol has been studied particularly for outcomes such as metabolic markers, insulin sensitivity, and ovulation.
- The 2023 International Evidence-Based Guideline for PCOS states that there is insufficient high-quality evidence for a specific inositol type, dose, or combination.
- In PCOS-related infertility, the effects of inositol on ovulation, clinical pregnancy, and live birth are not yet sufficiently clear.
- Oral inositol data should not be directly extrapolated to an intravenous “inositol infusion.”
What is inositol?
Inositol is a cyclic polyol that plays a role in cell membrane phosphoinositides and second messenger systems. Different isomers are found in the human body. Myo-inositol is the most common form; D-chiro-inositol has been studied particularly in the context of insulin signaling and glucose metabolism.
Why is it being studied in PCOS?
Insulin resistance, hyperandrogenism, irregular ovulation, and metabolic risks may be common in PCOS. Inositol’s ability to influence pathways associated with insulin signaling and ovarian function has led to research in this area. Some studies have reported favorable changes in insulin, glucose, or other metabolic markers; clinical response may vary from person to person and depending on the formulation used.
What does the international PCOS guideline say?
The 2023 International Evidence-Based Guideline for PCOS states that inositol may be considered based on women’s preferences and values. The guideline emphasizes that, alongside possible metabolic improvements, benefits for clinical outcomes such as weight, hirsutism, and ovulation are more limited; because of the quality of the available evidence, a specific inositol form, dose, or combination cannot be generally recommended.
Its role in infertility treatment
There are studies on the effects of inositol on ovulation, clinical pregnancy, and live birth rates in PCOS-related infertility; however, the current guideline does not yet consider these results sufficiently conclusive. Therefore, in the context of infertility, inositol should be considered not as a method that replaces established ovulation induction or assisted reproductive treatments, but as a complementary option that can be discussed with a physician when needed.
Its role in weight and metabolic health
Inositol is not a weight loss treatment on its own. Its potential contribution to metabolic markers in PCOS should not be considered separately from the broader treatment plan, which includes nutrition, physical activity, sleep, body composition, and, when needed, metformin or obesity pharmacotherapy. The target to be monitored should be determined at the outset.
The distinction between oral and IV use
PCOS guidelines and clinical studies primarily evaluate oral inositol products. These data do not show that intravenous inositol administration will provide the same clinical outcomes. When IV use is considered, the specific pharmaceutical product, route of administration, and human safety and efficacy data should be examined separately.
Safety and product quality
Although inositol is generally known as a well-tolerated oral supplement, gastrointestinal complaints may occur. Supplement products may vary in content, dose, purity, and myo-inositol/D-chiro-inositol ratios. An individualized assessment should be performed when pregnancy planning, pregnancy, breastfeeding, diabetes treatment, or other medications are involved.
Our approach at our Bodrum clinic
We evaluate inositol, particularly in the context of PCOS and metabolic health, not as a stand-alone product, but alongside the individual’s insulin resistance, menstrual regularity, signs of androgen excess, weight-body composition, pregnancy goals, and medications used. If an oral product is to be selected, we determine the form, dose, and monitoring target at the outset. IV inositol is not considered an extension of oral studies; it is approached as an intervention requiring a separate product and separate evidence.
Frequently asked questions
Can inositol be used in PCOS?
Current guidelines state that it may be considered based on personal preferences and goals. There may be a potential contribution to metabolic measures; uncertainties remain regarding the magnitude of clinical outcomes and which form is most appropriate.
Is there an ideal ratio of myo-inositol to D-chiro-inositol?
Although different ratios are widely used on the market, the current international guideline does not recommend a specific form, dose, or combination as standard based on high-quality evidence.
Does inositol help with weight loss?
It should not be considered a treatment that provides lasting weight loss on its own. It may be part of the metabolic plan in PCOS; it is considered alongside nutrition, physical activity, sleep, and, when needed, medical treatments.
Does inositol replace infertility treatment?
The current evidence regarding ovulation, clinical pregnancy, and live birth is not yet sufficiently conclusive. Therefore, it should be considered a complementary option in individual cases, not a replacement for standard infertility treatments.
Related content
References
- Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
- International PCOS Network / ASRM. Inositol recommendations, sections 4.7 and 5.8.
- Inositol for Polycystic Ovary Syndrome: systematic review and meta-analysis informing the 2023 guideline update. J Clin Endocrinol Metab.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: 10 September 2026
Disclaimer: This content is intended for general medical information; it does not replace a personal diagnosis or treatment recommendation.
